Resorbable Embolization Technology

Built from organic biocompatible materials

Restores blood flow to the targeted area

Minimizes the impact of non-target embolization

Resorbable Microspheres for Improved Patient Outcomes

Permanent microspheres have existed for more than 20 years, and are routinely used to treat liver cancer, uterine fibroids and benign prostate hyperplasia. Resorbable microspheres can be used to treat a range of new indications where it is desirable to restore blood flow to the targeted area after the desired therapeutic effect has been achieved.

This restoration of flow can be necessary to ensure a sufficient long term blood supply to downstream tissue, to minimize the effect of non-target embolization or to facilitate repeat procedures. The technology has the potential to deliver therapeutic agents which opens up many additional treatments.

These resorbable microspheres have new applications in Knee Osteoarthritis (KOA), Adhesive Capsulitis (Frozen Shoulder), treatment of pain pre- and post-knee replacement, various tendinopathies including plantar fasciitis, Pancreatic Cancer and more, along with the potential to replace permanent beads in existing applications.

Learn More About Clinical Applications

Patented Process to Leave No Trace

There is a strong and growing patient preference not to leave anything behind in the body.

CrannMed’s resorbable technology is built from organic biocompatible materials. Microsphere degradation within the vasculature is controlled using an embedded enzyme that exclusively targets the base material of the microsphere. Our pre-clinical trials have given us confidence our technology leaves no trace. Our microspheres have no other targets within the human body which ensures a controlled degradation of the microspheres completely independent to the physiological response of the patient.

The duration of reabsorption can be customized from a few hours to six months. The manufacturing technology ensures market leading size distribution, long term iso-buoyancy and excellent deliverability; demonstrating fill efficiency in challenge testing. A time-lapse of angiographic images here conveys the impact of embolization with SakuraBead over the period of resorption. Complete revascularization occurs by T4.

Both the technology and the manufacturing process are protected by a suite of international patent applications.

SakuraBead technology is patent protected by patent number US 12083242 B2

A New Technology called SakuraBead

At CrannMed we are developing resorbable embolic microspheres to unlock the growing potential of vascular embolization. We call this technology SakuraBead, and it will possess wide-ranging applications. Our first commercial application focus is to treat the debilitating pain associated with knee osteoarthritis.

Musculoskeletal embolization was pioneered in Japan. Cherry Blossom (Sakura) trees are synonymous with Japan & Japanese culture. The Sakura trees are known for the transience of their blossoms. In a nod to this piece of history and as a symbolism of natural impermanence, we feel it is the perfect name for our technology.